Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.4B 209M 182M 172M 156M 293M 20.04B 294M 2.06B 793M 10.21B 786M 768M 32.94B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 1.18B 176M 153M 144M 132M 247M 16.86B 247M 1.73B 667M 8.59B 661M 646M 27.71B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.32%
Yield 2024 *
-
Yield 2025 0.65%
08-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-16 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-08 Shanghai Rightongene Biotechnology's boards elects chairman RE
25-08-28 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
25-02-19 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
25-02-17 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
25-01-02 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
24-10-29 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
1 day+1.48%
1 week+7.50%
1 month+2.46%
3 months+13.66%
6 months-7.14%
Current year-3.68%
1 week 22.38
Extreme 22.38
25.75
1 month 22.38
Extreme 22.38
25.8
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
33.27
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 2024-07-21
Director of Finance/CFO 34 2025-01-26
Investor Relations Contact - -
Director TitleAgeSince
Chairman 69 2024-07-21
Director/Board Member 41 2019-05-12
Director/Board Member 53 2023-08-23
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+7.50%-8.38%-34.74% 206M
+2.69%+1.50%+198.24%+587.58% 23.33B
+3.78%+9.99%+527.49%+97.88% 10.31B
+1.31%+0.62%-35.80%-19.45% 9.76B
+5.37%+13.16%-2.09% - 8.66B
-0.01%-0.50%+100.02%+62.13% 6.55B
+0.86%+1.92%-27.31%-20.73% 5.76B
-2.31%+2.70%-2.56%-11.97% 4.43B
+0.89%+8.70%+66.62%+72.10% 4B
+7.53%+10.21%-13.10%-24.70% 2.77B
Average +2.16%+6.90%+80.31%+78.68% 7.58B
Weighted average by Cap. +2.35%+6.18%+137.38%+223.17%

Financials

2024 2025
Net sales 242M 36.18M 31.55M 29.71M 27.06M 50.73M 3.47B 50.8M 356M 137M 1.77B 136M 133M 5.7B 177M 26.47M 23.08M 21.74M 19.8M 37.12M 2.54B 37.16M 260M 100M 1.29B 99.43M 97.23M 4.17B
Net income -15.76M -2.35M -2.05M -1.93M -1.76M -3.3M -226M -3.3M -23.15M -8.92M -115M -8.84M -8.65M -371M -50.38M -7.52M -6.56M -6.18M -5.63M -10.55M -721M -10.56M -73.98M -28.52M -367M -28.26M -27.63M -1.18B
Net Debt -210M -31.4M -27.38M -25.79M -23.49M -44.03M -3.01B -44.09M -309M -119M -1.53B -118M -115M -4.95B -222M -33.22M -28.96M -27.28M -24.84M -46.58M -3.18B -46.64M -327M -126M -1.62B -125M -122M -5.23B
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
327
Date Price Change Volume
26-09-21 CN¥25.38 +1.48% 879,088
26-09-21 CN¥25.01 +4.73% 1,417,583
26-09-18 CN¥23.88 +0.93% 934,070
26-09-17 CN¥23.66 +2.74% 1,014,777
26-09-16 CN¥23.03 +1.63% 694,447

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688217 Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!